Merck & Company Inc (MRK)vsPuma Biotechnology Inc (PBYI)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
PBYI
Puma Biotechnology Inc
$9.12
-0.55%
HEALTHCARE · Cap: $492.97M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 28687% more annual revenue ($66.57B vs $231.24M). PBYI leads profitability with a 11.6% profit margin vs 4.8%. PBYI appears more attractively valued with a PEG of 0.03. PBYI earns a higher WallStSmart Score of 67/100 (B-).
MRK
Hold36
out of 100
Grade: F
PBYI
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
+68.6%
Fair Value
$21.16
Current Price
$9.12
$12.04 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Growing faster than its price suggests
Conservative balance sheet, low leverage
Earnings expanding 35.8% YoY
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Smaller company, higher risk/reward
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : PBYI
The strongest argument for PBYI centers on PEG Ratio, Debt/Equity, EPS Growth. PEG of 0.03 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : PBYI
The primary concerns for PBYI are Market Cap, Altman Z-Score.
Key Dynamics to Monitor
PBYI carries more volatility with a beta of 1.23 — expect wider price swings.
PBYI is growing revenue faster at 7.8% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
PBYI scores higher overall (67/100 vs 36/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Puma Biotechnology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and internationally. The company is headquartered in Los Angeles, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?